This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA

Art Krieg, MD
Chief Executive Officer at Zola Therapeutics
Speaker

Profile

Art Krieg, MD founded Zola Therapeutics in 2023, and serves as CEO. Previously Art founded Checkmate Pharmaceuticals, until its acquisition by Regeneron in 2022, RaNA Therapeutics (subsequently Translate Bio, acquired by Sanofi); and Coley Pharmaceutical Group until it’s acquisition by Pfizer in 2008. Art served as CSO of Pfizer’s Oligonucleotide Therapeutics Unit from 2008 to 2011 and co-founded the first antisense journal, Nucleic Acid Therapeutics and the Oligonucleotide Therapeutics Society, for which he recently served as President. He has published more than 250 scientific papers, and is an inventor on >50 issued US patents covering oligonucleotide technologies.

Agenda Sessions

  • Activating Anti-tumor Immunity with RNA/DNA Hybrid Agonists of TLR7/8/9

    4:45pm